Immunogen (IMGN) Tops Q4 EPS by 1c
Immunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $39.45 million versus the consensus estimate of $32.71 million.
For 2018, ImmunoGen expects:
- revenues between $60 million and $65 million;
- operating expenses between $185 million and $190 million; and
- cash and cash equivalents at December 31, 2018 between $115 million and $120 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.